Chronic myelogenous leukemia

被引:1
作者
Hochhaus, A. [1 ]
La Rosee, P. [1 ]
Eigendorff, E. [1 ]
Ernst, T. [1 ]
机构
[1] Univ Klinikum Jena, Hamatol Onkol Abt, D-07740 Jena, Germany
来源
INTERNIST | 2015年 / 56卷 / 04期
关键词
Tyrosine kinase inhibitors; Interferon-alpha; Allogeneic stem cell transplantation; Minimal residual disease; CHRONIC MYELOID-LEUKEMIA; DURABLE CYTOGENETIC RESPONSES; TYROSINE KINASE INHIBITORS; PLUS INTERFERON-ALPHA; 24-MONTH FOLLOW-UP; CHRONIC-PHASE; BCR-ABL; IMATINIB-RESISTANT; MOLECULAR RESPONSE; ACCELERATED PHASE;
D O I
10.1007/s00108-014-3594-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The advent of tyrosine kinase inhibitors (TKI) has improved the prognosis and outcome of patients with chronic myelogenous leukemia (CML) considerably. Compared with imatinib, the first-line use of second-generation inhibitors nilotinib and dasatinib has led to faster and deeper molecular remissions accompanied by a differential adverse effect profile. An essential part of the management of CML patients is the guideline-based application of cytogenetics and standardized polymerase chain reaction techniques to regularly assess the remission status. Long-lasting treatment-free remission in a minority of patients led to hopes for the curability of CML in a significant minority of patients. The use of interferon alpha combined with or after TKI therapy is associated with the induction of an immune response toward the leukemic clone. This innovative treatment approach is currently under prospective investigation to improve long-term response. The coordinated cooperation of academic and regional hospitals, office-based hematologists, laboratories, and patient representatives allows for up-to-date patient care and the early use of new therapeutic options in patients at risk.
引用
收藏
页码:333 / 343
页数:11
相关论文
共 46 条
  • [1] Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
    Apperley, Jane F.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Roy, Lydia
    Roboz, Gail J.
    Rosti, Gianantonio
    Bullorsky, Eduardo O.
    Abruzzese, Elisabetta
    Hochhaus, Andreas
    Heim, Dominik
    de Souza, Carmino A.
    Larson, Richard A.
    Lipton, Jeffrey H.
    Khoury, H. Jean
    Kim, Hyeoung-Joon
    Sillaber, Christian
    Hughes, Timothy P.
    Erben, Philipp
    Van Tornout, Jan
    Stone, Richard M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3472 - 3479
  • [2] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
    Baccarani, Michele
    Deininger, Michael W.
    Rosti, Gianantonio
    Hochhaus, Andreas
    Soverini, Simona
    Apperley, Jane F.
    Cervantes, Francisco
    Clark, Richard E.
    Cortes, Jorge E.
    Guilhot, Francois
    Hjorth-Hansen, Henrik
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Larson, Richard A.
    Lipton, Jeffrey H.
    Mahon, Francois-Xavier
    Martinelli, Giovanni
    Mayer, Jiri
    Mueller, Martin C.
    Niederwieser, Dietger
    Pane, Fabrizio
    Radich, Jerald P.
    Rousselot, Philippe
    Saglio, Giuseppe
    Saussele, Susanne
    Schiffer, Charles
    Silver, Richard
    Simonsson, Bengt
    Steegmann, Juan-Luis
    Goldman, John M.
    Hehlmann, Ruediger
    [J]. BLOOD, 2013, 122 (06) : 872 - 884
  • [3] Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    de Souza, Carmino Antonio
    Guilhot, Francois
    Duvillie, Ladan
    Pavlov, Dmitri
    Gogat, Karin
    Countouriotis, Athena M.
    Gambacorti-Passerini, Carlo
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (01) : 69 - 81
  • [4] Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
    Burchert, Andreas
    Mueller, Martin C.
    Kostrewa, Philippe
    Erben, Philipp
    Bostel, Tilman
    Liebler, Simone
    Hehlmann, Ruediger
    Neubauer, Andreas
    Hochhaus, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1429 - 1435
  • [5] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
    Cortes, J. E.
    Kim, D. -W.
    Pinilla-Ibarz, J.
    le Coutre, P.
    Paquette, R.
    Chuah, C.
    Nicolini, F. E.
    Apperley, J. F.
    Khoury, H. J.
    Talpaz, M.
    DiPersio, J.
    DeAngelo, D. J.
    Abruzzese, E.
    Rea, D.
    Baccarani, M.
    Mueller, M. C.
    Gambacorti-Passerini, C.
    Wong, S.
    Lustgarten, S.
    Rivera, V. M.
    Clackson, T.
    Turner, C. D.
    Haluska, F. G.
    Guilhot, F.
    Deininger, M. W.
    Hochhaus, A.
    Hughes, T.
    Goldman, J. M.
    Shah, N. P.
    Kantarjian, H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) : 1783 - 1796
  • [6] Cortes JE, 2014, BLOOD, V124
  • [7] Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
    Cortes, Jorge
    Rousselot, Philippe
    Kim, Dong-Wook
    Ritchie, Ellen
    Hamerschlak, Nelson
    Coutre, Steven
    Hochhaus, Andreas
    Guilhot, Francois
    Saglio, Giuseppe
    Apperley, Jane
    Ottmann, Oliver
    Shah, Neil
    Erben, Philipp
    Branford, Susan
    Agarwal, Prasheen
    Gollerkeri, Ashwin
    Baccarani, Michele
    [J]. BLOOD, 2007, 109 (08) : 3207 - 3213
  • [8] Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)
    Cortes, Jorge E.
    Wetzler, Meir
    Lipton, Jeffrey H.
    Khoury, H. Jean
    Kropf, Patricia
    Michallet, Mauricette
    Baccarani, Michele
    Rea, Delphine
    Chuah, Charles
    Digumarti, Raghunadharao
    Parikh, Purvish M.
    Li, Elizabeth
    Munteanu, Mihaela C.
    Brown, Peter D.
    Nicolini, Franck E.
    [J]. BLOOD, 2013, 122 (21)
  • [9] Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Bruemmendorf, Tim H.
    Kim, Dong-Wook
    Turkina, Anna G.
    Shen, Zhi-Xiang
    Pasquini, Ricardo
    Khoury, H. Jean
    Arkin, Steven
    Volkert, Angela
    Besson, Nadine
    Abbas, Richat
    Wang, Junyuan
    Leip, Eric
    Gambacorti-Passerini, Carlo
    [J]. BLOOD, 2011, 118 (17) : 4567 - 4576
  • [10] Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
    Cortes, Jorge E.
    Baccarani, Michele
    Guilhot, Francois
    Druker, Brian J.
    Branford, Susan
    Kim, Dong-Wook
    Pane, Fabrizio
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Kalaycio, Matt
    Moiraghi, Beatriz
    Rowe, Jacob M.
    Tothova, Elena
    De Souza, Carmino
    Rudoltz, Marc
    Yu, Richard
    Krahnke, Tillmann
    Kantarjian, Hagop M.
    Radich, Jerald P.
    Hughes, Timothy P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 424 - 430